Weight loss drug could be supplied to UK ‘in weeks’ after new format approval
Mounjaro is a diabetes drug that was authorised by the MHRA to help obese and overweight adults with weight management and loss in November last year.
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.A weight loss drug newly approved in a four-dose injection pen format by the Medicines and Healthcare products Regulatory Agency (MHRA) could be supplied to the UK “within weeks”.
Mounjaro, also known as tirzepatide, is a diabetes drug that was authorised by the MHRA to help obese and overweight adults with weight management and loss in November last year.
US pharmaceutical company Eli Lilly’s Mounjaro “KwikPen” gives four doses of the drug for once-a-week treatment over a month.
The public health importance of safe and effective treatments to help manage diabetes and obesity, which can have a significant impact on people’s health, is clear
President and general manager of UK and Northern Europe at Lilly, Laura Steele, said: “The MHRA is the first major regulator in the world to issue marketing authorisation for the alternative KwikPen presentation for tirzepatide, demonstrating their clear focus on speeding innovation to help patients.
“This will enable Lilly to begin supply to the UK within weeks.”
Mounjaro KwikPen has been approved to treat adults with type 2 diabetes and for weight management in obese adults, as well as overweight adult patients who have weight-related health problems like prediabetes, high blood pressure, high cholesterol, or heart problems.
Julian Beach, MHRA interim executive director of healthcare quality and access, said: “The public health importance of safe and effective treatments to help manage diabetes and obesity, which can have a significant impact on people’s health, is clear.
“This approval enables access to the approved Mounjaro pen in a more convenient presentation of a month’s treatment, of one dose per week.”
The jab was given the green light for NHS use in September last year by the National Institute for Health and Care Excellence (Nice) as an option for patients with type 2 diabetes who do not have the condition under control, but Nice has yet to approve the use of the drug in the NHS for obesity.
The active ingredient in the drug helps to reduce sugar levels in people with type 2 diabetes when their levels are high, and works as a weight management drug by making a patient feel full and less hungry, and making them experience fewer food cravings.
Supporting people with type 2 diabetes to lose weight and manage their blood sugar levels is key to reducing the risk of diabetes-related complications
The MHRA’s newest authorisation is based on the results of a bridging study which showed the efficacy and safety of the multidose Mounjaro KwikPen are expected to be the same as those for the single-dose pen.
Douglas Twenefour, head of care at Diabetes UK, said: “We hope the MHRA’s approval of this device will help people living with type 2 diabetes, who are eligible, to access this effective treatment.
“Supporting people with type 2 diabetes to lose weight and manage their blood sugar levels is key to reducing the risk of diabetes-related complications, and tirzepatide (Mounjaro) expands the range of treatment options available to help people achieve this.”
The MHRA warned the drug may affect how well the contraceptive pill works in obese or overweight female patients.
It also listed potential side effects of the medicine, including nausea, diarrhoea, vomiting – which usually goes away over time – and constipation.
Low blood sugar is also “very common” in patients with diabetes, the agency added.
The MHRA said it will keep the safety and effectiveness of Mounjaro under close review.